Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis

NCT04088721 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinitis

Interventions

BIOLOGICAL: AD17002
OTHER: Formulation Buffer

Sponsor

Advagene Biopharma Co. Ltd.

Collaborators

[object Object]
[object Object]